To the Editor In their recent Original Investigation, Greco et al1 report early results from the PROSINT trial, which randomized 30 patients with intermediate-risk prostate cancer to 5-fraction stereotactic body radiotherapy (9 Gy × 5) vs 24-Gy single-dose radiotherapy (SDRT). After a median follow-up of 4 years, biochemical control rates were similar (86% vs 77%). As a proof-of-concept study, it forms the basis for larger, ongoing trials.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Squires BS, Krauss DJ. Single-Dose Radiotherapy for Prostate Cancer—Lessons Learned From Single-Fraction High-Dose-Rate Brachytherapy. JAMA Oncol. 2021;7(10):1572. doi:10.1001/jamaoncol.2021.2691
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.